Home|Journals|Articles by Year|Audio Abstracts

Original Article

Validated Eco-Friendly Chromatographic Methods for Simultaneous Determination of Sacubitril and Valsartan in Spiked Human Plasma and in Pharmaceutical Formulation

Amal Mahmoud Abou Al Alamein.


Two eco-friendly chromatographic approaches are developed for simultaneous quantification of Sacubitril (SAC) and Valsartan (VAL) in combined formulation. The first method depended on isocratic HPLC separation of the two medications on the reversed phase InertsiL ODS-3 column “C18 (5 μm, 150mm × 4.0 mm, i.d.)” at ambient temperature utilizing a green mobile phase consisting of methanol: ethanol: water (40:30:30, by volumes) +0.1% triethyl amine, pH 3.5 with UV detection at 267 nm. Linearity was attained for both drugs at concentration ranges 1–300 μg. mL-1 in tablets formulation and 0.25–50 μg. mL-1 in spiked human plasma. Second method was HPTLC which based on separation of the two analytes with densitometric measurements of their resolved spots at 260 nm. Complete separation was performed on HPTLC plates (10 cm × 10 cm), 0.1 mm Nano silica gel with particle size 6–9 μm F254 (Merck) using ethyl acetate: methanol: glacial acid (9:1:0.1, by volumes) as a green mobile phase. The data of linear regression analysis was used for the regression line in concentration range of 1.5–4.5 and 0.8–4.5 μg. spot-1 for Sacubitril and Valsartan, respectively and 9–75 ng. spot-1 for both drugs in spiked human plasma.

Key words: Sacubitril, Valsartan, HPLC, HPTLC, Green chemistry

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.